AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

Patients with actionable genomic alterations were previously treated with an approved targeted therapy and platinum ... as a monotherapy and in combination with other anticancer treatments in various ...

AstraZeneca and Daiichi Sankyo have submitted a new biologics license application (BLA) for accelerated approval for ...

AstraZeneca and Daiichi Sankyo have changed up their approval plans for a closely ... AstraZeneca and Daiichi have found ...

Aileen Lamb hopes the approval of a new cancer treatment drug will give patients 'hope', after she was given the all clear ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

Researchers in the field have a keen interest in combination strategies, such as CAR T-cell therapy plus immune checkpoint ...

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...

The asset has been shown to promising anti-tumour profile when administered alone or in combination with palbociclib and thus ...

Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ET. Company Participants. Hiroyuki Okuzawa - Representative Director, Presi ...